Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (avaa uuden ikkunan)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Lähde‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Arkistoitu‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (avaa uuden ikkunan)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (avaa uuden ikkunan)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Lähde‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Arkistoitu‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (avaa uuden ikkunan)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (avaa uuden ikkunan)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Lähde‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Arkistoitu‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (avaa uuden ikkunan)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (avaa uuden ikkunan)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Lähde‎: Blood 2003;102(4):1529-30.

Arkistoitu‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (avaa uuden ikkunan)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (avaa uuden ikkunan)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Lähde‎: Transfusion 2007;47(10):1830-6.

Arkistoitu‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (avaa uuden ikkunan)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (avaa uuden ikkunan)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Lähde‎: Iran J Blood Cancer 2009;1(4):147-50.

Arkistoitu‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (avaa uuden ikkunan)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (avaa uuden ikkunan)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Lähde‎: Int J Hematol 2012;95(1):51-6.

Arkistoitu‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (avaa uuden ikkunan)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (avaa uuden ikkunan)

Perrine SP.

Lähde‎: Pediatr Ann 2008;37(5):339-46.

Arkistoitu‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (avaa uuden ikkunan)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (avaa uuden ikkunan)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Lähde‎: Sci Rep. 2022;12(1):2752.

Arkistoitu‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (avaa uuden ikkunan)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (avaa uuden ikkunan)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Lähde‎: Haematologica 2004;89(10):1172-8.

Arkistoitu‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (avaa uuden ikkunan)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (avaa uuden ikkunan)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Lähde‎: Arch Iran Med 2009;12(3):295-7.

Arkistoitu‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (avaa uuden ikkunan)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (avaa uuden ikkunan)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Lähde‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Arkistoitu‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (avaa uuden ikkunan)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (avaa uuden ikkunan)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Lähde‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Arkistoitu‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (avaa uuden ikkunan)

Fetal globin gene inducers: novel agents and new potential. (avaa uuden ikkunan)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Lähde‎: Ann N Y Acad Sci 2010;1202:158-64.

Arkistoitu‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (avaa uuden ikkunan)